Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18
Biotech
UniQure stock surges after FDA U-turn clears path to filing
The FDA gave the biotech the OK to file for accelerated approval after previously demanding data from another trial.
Nick Paul Taylor
Jun 17, 2026 9:10am
Jazz, AbCellera strike TCE discovery and development deal
Jun 17, 2026 7:00am
How NEC's AI and oral delivery system are redefining personalized cancer therapy
Brought to you by
NEC Bio
Vedana surfaces with $46M to develop migraine prevention therapies
Jun 17, 2026 9:48am
Fierce Biotech Fundraising Tracker '26: Triveni Bio & more
Jun 17, 2026 9:30am
Fierce Pharma
PwC projects continued growth for rest of 2026, fueled by M&A
Jun 17, 2026 5:00am
More News
FDA appears less prickly toward Moderna mRNA flu shot
Jun 16, 2026 2:46pm
Lilly buys 4E to beef up its non-opioid pain pipeline
Jun 16, 2026 2:34pm
Altaris scoops up AI drug development outfit for $375M
Jun 16, 2026 12:13pm
Edgewise data power rival to BMS and Cytokinetics toward phase 3
Jun 16, 2026 10:39am
See more stories